نتایج جستجو برای: early virologic response

تعداد نتایج: 1595197  

2016
Tatsuo Kanda Shingo Nakamoto Reina Sasaki Masato Nakamura Shin Yasui Yuki Haga Sadahisa Ogasawara Akinobu Tawada Makoto Arai Shigeru Mikami Fumio Imazeki Osamu Yokosuka

BACKGROUND Direct-acting antiviral agents against HCV with or without peginterferon plus ribavirin result in higher eradication rates of HCV and shorter treatment duration. We examined which is better for predicting persistent virologic response, the assessment of serum HCV RNA at 12 or 24 weeks after the end of treatment for predicting sustained virologic response (SVR12 or SVR24, respectively...

2017
Eduardo Arathoon Asad Bhorat Rodica Silaghi Herta Crauwels Ludo Lavreys Lotke Tambuyzer Ben Van Baelen Simon Vanveggel Magda Opsomer

OBJECTIVE VIOLIN (TMC125IFD3002; NCT01422330) evaluated the safety, tolerability, and pharmacokinetics of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected patients. METHODS In a 48-week, phase IV, single-arm, multicenter study, patients on prior antiretroviral therapy (⩾8 weeks) who needed to change regimen for virologic failure (viral load ⩾ 500 copies/mL) or ...

2015
Shingo Nakamoto Fumio Imazeki Makoto Arai Shin Yasui Masato Nakamura Yuki Haga Reina Sasaki Tatsuo Kanda Hiroshi Shirasawa Osamu Yokosuka Johannes Haybaeck

We examined whether hepatitis C virus (HCV) genotype 1b core- and NS5A-region mutations are associated with response to peginterferon α-2b plus ribavirin combination therapy. A total of 103 patients with high HCV genotype 1b viral loads (≥ 100 KIU/mL) were treated with the combination therapy. Pretreatment mutations in the core region and interferon sensitivity determining region (ISDR) in the ...

Journal: :Hepatology 2001
K L Lindsay C Trepo T Heintges M L Shiffman S C Gordon J C Hoefs E R Schiff Z D Goodman M Laughlin R Yao J K Albrecht

This international, randomized, active-controlled, parallel-group, double-blind dose-finding study compared peginterferon alfa-2b (PegIntron) to interferon alfa-2b for the initial treatment of compensated chronic hepatitis C. We randomly assigned 1,219 subjects to receive either the standard three-times-weekly (TIW) interferon alfa-2b dose (3 MIU) or the once-weekly (QW) peginterferon alfa-2b (...

Journal: :The Journal of infectious diseases 2004
Patricia M Flynn Bret J Rudy Steven D Douglas Janet Lathey Stephen A Spector Jaime Martinez Margarita Silio Marvin Belzer Lawrence Friedman Lawrence D'Angelo James McNamara Janice Hodge Michael D Hughes Jane C Lindsey

BACKGROUND Adolescents represent the fastest growing demographic group of new human immunodeficiency virus (HIV) infections in the United States. At present, there is little information available about their response to therapy. METHODS We studied 120 adolescents infected via high-risk behaviors who began receiving highly active antiretroviral therapy (HAART), to determine their virologic and...

Journal: :The New England journal of medicine 2011
Stefan Zeuzem Pietro Andreone Stanislas Pol Eric Lawitz Moises Diago Stuart Roberts Roberto Focaccia Zobair Younossi Graham R Foster Andrzej Horban Peter Ferenci Frederik Nevens Beat Müllhaupt Paul Pockros Ruben Terg Daniel Shouval Bart van Hoek Ola Weiland Rolf Van Heeswijk Sandra De Meyer Don Luo Griet Boogaerts Ramon Polo Gaston Picchio Maria Beumont

BACKGROUND Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin. METHODS In this randomized, phase 3 trial, we evaluated the addition of telaprevir to peginterferon alfa-2a plus ribavirin in patients with HCV genotype 1 infection who had no response or a partial response to previous...

Journal: :The New England journal of medicine 2009
John G McHutchison Gregory T Everson Stuart C Gordon Ira M Jacobson Mark Sulkowski Robert Kauffman Lindsay McNair John Alam Andrew J Muir

BACKGROUND Current therapy for chronic hepatitis C virus (HCV) infection is effective in less than 50% of patients infected with HCV genotype 1. Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV RNA levels in early studies. METHODS We randomly assigned patients infected with HCV genotype 1 to one of three telaprevir groups or to the c...

Journal: :HIV clinical trials 2013
M R Nelson R A Elion C J Cohen A Mills S L Hodder S Segal-Maurer M Bloch W Garner B Guyer S Williams S Chuck S Vanveggel H Deckx M Stevens

OBJECTIVES Week 96 efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) was compared to efavirenz (EFV) in subset of 1,096 subjects who received emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in pooled data from 2 phase 3 studies. METHODS ECHO and THRIVE are double-blind, double-dummy, randomized, active-controlled, non-inferiority phase 3...

Journal: :Gastroenterology 2011
Kathleen B Schwarz Regino P Gonzalez-Peralta Karen F Murray Jean P Molleston Barbara A Haber Maureen M Jonas Philip Rosenthal Parvathi Mohan William F Balistreri Michael R Narkewicz Lesley Smith Steven J Lobritto Stephen Rossi Alexandra Valsamakis Zachary Goodman Patricia R Robuck Bruce A Barton

BACKGROUND & AIMS Although randomized trials of adults infected with hepatitis C virus (HCV) have shown that ribavirin increases the efficacy of pegylated interferon (PEG), such trials have not been performed in children. We conducted a randomized controlled trial of PEG and ribavirin, compared with PEG and placebo, in children 5 to 17 years old with chronic hepatitis C. METHODS HCV RNA-posit...

Journal: :Antimicrobial agents and chemotherapy 2014
Edward J Gane Régine Rouzier Alicja Wiercinska-Drapalo Dominique G Larrey Peter N Morcos Barbara J Brennan Sophie Le Pogam Isabel Nájera Rosemary Petric Jonathan Q Tran Rohit Kulkarni Ying Zhang Patrick Smith Ellen S Yetzer Nancy S Shulman

Danoprevir (DNV) is a hepatitis C virus (HCV) protease inhibitor that achieves high sustained virologic response (SVR) rates in combination with peginterferon alfa-2a-ribavirin in treatment-naive HCV genotype 1 (G1)-infected patients. This study explored the efficacy and safety of ritonavir-boosted DNV (DNVr) plus peginterferon alfa-2a-ribavirin in G1-infected prior peginterferon-ribavirin null...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید